Veraxa Biotech is trading 9.01% up in pre-market at $1.21; no clear company-specific or market-driven reason for the gain is confirmed. - October 14 close: $1.11. - The company release page lists October 7 as its latest release. The BiTAC-ADC proof-of-concept presentation, announced October 13, is prior news—not a confirmed October 15 catalyst. - The overnight backdrop is risk-off, but major indices are mixed and do not explain the gain.